Nephropathic cystinosis: an update on genetic conditioning

Pediatr Nephrol. 2021 Jun;36(6):1347-1352. doi: 10.1007/s00467-020-04638-9. Epub 2020 Jun 20.

Abstract

Cystinosis is an autosomal recessive lysosomal storage disorder caused by CTNS gene mutations. The CTNS gene encodes the protein cystinosin, which transports free cystine from lysosomes to cytoplasm. In cases of cystinosin deficiency, free cystine accumulates in lysosomes and forms toxic crystals that lead to tissue and organ damage. Since CTNS gene mutations were first described, many variations have been identified that vary according to geographic region, although the phenotype remains the same. Cystinosis is a hereditary disease that can be treated with the cystine-depleting agent cysteamine. Cysteamine slows organ deterioration, but cannot treat renal Fanconi syndrome or prevent eventual kidney failure; therefore, novel treatment modalities for cystinosis are of great interest to researchers. The present review aims to highlight the geographic differences in cystinosis-specifically in terms of its genetic aspects, clinical features, management, and long-term complications.

Keywords: Clinical features; Cystinosis; Disparities; Genetics; Geographic regions; Management.

Publication types

  • Review

MeSH terms

  • Amino Acid Transport Systems, Neutral* / genetics
  • Cysteamine / therapeutic use
  • Cystine / metabolism
  • Cystinosis* / diagnosis
  • Cystinosis* / drug therapy
  • Cystinosis* / genetics
  • Fanconi Syndrome* / diagnosis
  • Fanconi Syndrome* / genetics
  • Fanconi Syndrome* / therapy
  • Humans
  • Mutation

Substances

  • Amino Acid Transport Systems, Neutral
  • Cystine
  • Cysteamine